Marek Poszepczynski
Keine laufenden Positionen mehr
Profil
Marek Poszepczynski worked as a Licensing Director at Biovitrum AB from 2002 to 2008.
He then worked as a Vice President of Business Development at Karolinska Development AB from 2008 to 2010.
From 2010 to 2012, he was a Lead Equity Analyst at Svenska Handelsbanken AB.
He also worked as a Vice President of Business Development at Axelar AB.
From 2012 to 2017, he was a Director of Business Development at Calliditas Therapeutics AB.
Prior to his business career, he graduated from the Royal Institute of Technology.
Ehemalige bekannte Positionen von Marek Poszepczynski
| Unternehmen | Position | Ende |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Corporate Officer/Principal | 01.03.2017 |
| SVENSKA HANDELSBANKEN AB | Corporate Officer/Principal | 01.01.2012 |
| KAROLINSKA DEVELOPMENT AB | Corporate Officer/Principal | 01.01.2010 |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | 01.01.2008 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | - |
Ausbildung von Marek Poszepczynski
| Royal Institute of Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SVENSKA HANDELSBANKEN AB | Finance |
| CALLIDITAS THERAPEUTICS AB | Health Technology |
| KAROLINSKA DEVELOPMENT AB | Finance |
| Private Unternehmen | 4 |
|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Svenska Handelsbanken AB (Broker)
 Svenska Handelsbanken AB (Broker) Investment Banks/BrokersFinance Svenska Handelsbanken AB (Broker) (Handelsbanken-Broker) is the broker/dealer division of Svenska Handelsbanken AB (STO: SHB-A; OTCMKTS: SVNLY) in Sweden. Headquartered in Stockholm, Handelsbanken-Broker was founded in 1871 and provides trading services to large corporates. The firm trades in equities, money market instruments, currencies, commodities and derivatives. | Finance |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
